- About I-SPY 2
The clinical trial is focused on determining if combining
investigation drugs to standard chemotherapy treatment is more
useful than just standard chemotherapy before surgery.
The I-SPY 2 Trial, which stands for Investigation of Serial
Studies to Predict Your Therapeutic Response with Imaging And
moLecular Analysis, is managed by a public and private partnership
known as the Biomarkers Consortium. While the University of
California, San Francisco is the lead site for the study, 20
locations across the country are participating in I-SPY 2.
The trial is centered around women with aggressive forms of
invasive breast cancer. While many factors contribute to a
patient’s eligibility in the trial, women must have tumors 2.5
centimeters or larger to be able to be screened for the study.
The trial features three separate phases: screening, treatment
A patient’s participation in the study typically lasts about six
months to a year. There are roughly 20 different trial sites for
I-SPY 2 and the program that began in March 2010 will continue
— Source: ispy2.org
Posted: Saturday, August 6, 2011 7:41 am
East Bay native Jo Chien is part of a team of researchers aiming
to change the way cancer research is conducted. The
Harvard-educated MD arrived at UCSF in 2009 to complete her
oncology fellowship and is now the principal investigator for the
university’s portion of I-SPY 2. In a briefly edited interview,
Chien discussed the project’s mission and its future.
Q: How is I-SPY 2 different than I-SPY 1?
Saturday, August 6, 2011 7:41 am.